secwatch.observer — SEC 8-K summary
======================================

Issuer:     BICYCLE THERAPEUTICS PLC (BCYC)
CIK:        0001761612
Form:       8-K
Filed at:   2022-07-12T23:59:59+00:00
Accession:  0001104659-22-079143
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bicycle Therapeutics expands Genentech immuno-oncology collaboration; receives $10M option exercise payment
--------------------------------------------------------------------------------

- Genentech exercised second option to add a new program to the existing 2020 collaboration, triggering a $10M payment to Bicycle.
- First expansion option under the same agreement was exercised in October 2021, also for $10M.
- Collaboration covers discovery and preclinical development of novel Bicycle-based immunotherapies against multiple targets.
- Bicycle's wholly owned oncology pipeline, including its immuno-oncology candidates, is not part of the collaboration.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1761612/000110465922079143/0001104659-22-079143-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1761612/000110465922079143/tm2220703d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-079143

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer